Webinar Recording: HOW TO USE TPMT AND NUDT15 PGX TO REDUCE THIOPURINES-RELATED ADVERSE REACTIONS
Summary of Webinar
Drs. Shannon Manzi and Gunter Scharer discuss how to use TPMT and NUDT15 pharmacogenetics (PGx) to guide thiopurines dosing and reduce adverse events. Dr. Scharer focuses on TPMT and NUDT15 testing and how to use the latest Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline to improve thiopurines dosing. Dr. Manzi shares her hands-on experience in developing a team-based precision medicine program to improve patient care and reduce cost of care at Boston Children’s Hospital.
About Presenters
Shannon Manzi, PharmD
Dr. Manzi is a clinical pharmacist and has practiced pediatric pharmacy for more than 20 years. She serves as the Director of the Clinical pharmacogenomics Service at Boston Children’s Hospital and is an Assistant Professor of Pediatrics at Harvard Medical School. Dr. Manzi is the member of the Clinical Pharmacogenetics Implementation Consortium (CPIC).
Gunter Scharer, MD, PhD
Dr. Scharer is a board-certified medical geneticist with 15+ years of clinical and laboratory experience. He is a renowned geneticist with deep experience in rare disorders and mitochondrial disease. Dr. Scharer is a member of the CPIC and Pharmacogenomics Research Network (PGRN).
Please fill in the form to access the webinar.
Insights into TPMT and NUDT15
TPMT & NUDT15: Two critical PGx genes to guide thiopurines dosing and reduce adverse events
Order the test
Learn more about RPRD’s NT (NUDT15 and TPMT) test.